辉瑞在Covid疫苗和药丸销售的驱动下,打破了Q4预期的收入,收入为17.8B美元。 Pfizer beats Q4 earnings expectations, driven by Covid vaccine and pill sales, with revenue at $17.8B.

辉瑞报告了强劲的第四季度收益，收入达到 178 亿美元，超出预期，这得益于其 Covid 疫苗和药丸的销售。 Pfizer reported strong fourth-quarter earnings, beating expectations with revenue of $17.8 billion, driven by sales of its Covid vaccine and pill. 经调整的收入达到63美分,高于预计的47美分。 Adjusted earnings reached 63 cents, higher than the predicted 47 cents. 该公司还受益于削减成本的措施,旨在到2025年节省45亿美元。 The company also benefited from cost-cutting measures, aiming for $4.5 billion in savings by 2025. 在癌症药物和心血管病治疗的支持下,非消费者产品销售额也增加了12%。 Non-Covid product sales also showed a 12% increase, supported by cancer drugs and treatments for cardiomyopathy.